Medical Condition

prodromal schizophrenia

Total Trials

1

Recruiting Now

1

Trial Phases

Various

Schizophrenia trials have been revitalized by the approval of muscarinic receptor agonists (xanomeline-trospium/KarXT) — the first non-dopaminergic antipsychotic approved in decades — validating a long-hypothesized cholinergic mechanism and opening new mechanistic territory. Negative symptom treatment and cognitive impairment associated with schizophrenia (CIAS) remain critical unmet needs with no approved therapies.

Active trials investigate M1/M4 muscarinic agonists, trace amine-associated receptor 1 (TAAR1) agonists (ulotaront), glycine transporter inhibitors, cognitive remediation combined with pharmacotherapy, and long-acting injectable formulations to improve adherence. PANSS total score and negative symptom subscales are standard primary endpoints.

Top Sponsors

Northwell Health 1 trial

Recruiting Clinical Trials

NCT05131035

Recruiting

Targeting Processing Speed Deficits to Improve Social Functioning and Lower Psychosis Risk

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology